ASAP Act
Summary
The ASAP Act (HR6130) mandates Medicare coverage for FDA-cleared blood-based dementia screening tests starting Jan 1, 2028. Labcorp ($LH) and Quest Diagnostics ($DGX) are the two largest independent lab operators with existing FDA-cleared blood-based dementia tests, making them primary beneficiaries of this new mandatory benefit category. The bill is in early legislative stages (referred to committee) with companion bill S3267 in the Senate, but the bipartisan sponsorship and 82 cosponsors indicate strong momentum for a mid-2027 passage timeline.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.ASAP Act mandates Medicare coverage for blood-based dementia tests — no cash-pay barrier for seniors starting 2028.
- 2.Primary beneficiaries: Labcorp ($LH) and Quest ($DGX), the two independent labs with existing FDA-cleared blood-based dementia tests.
- 3.Bill is early stage but has 82 cosponsors + Senate companion — strong bipartisan momentum for mid-2027 passage.
- 4.QuidelOrtho ($QDEL) and Revvity ($RVTY) have diagnostics exposure but lack direct FDA-cleared dementia blood tests — secondary beneficiaries at best.
Market Implications
Both $LH and $DGX have declined over the past 30 days (LH: -3.62% to $257.16; DGX: -2.55% to $191). This is NOT driven by dementia policy news; it reflects general market weakness in the healthcare services sector. The ASAP Act is a positive fundamental catalyst that is not yet priced into these stocks. As the bill progresses through committee and toward passage, the market should begin to price in the incremental revenue from mandatory Medicare coverage. Investors should view current price levels as attractive entry points given the de-risked regulatory pathway (FDA-cleared tests already exist) and the certainty of the January 1, 2028 effective date if passed.
Full Analysis
The ASAP Act (HR6130), introduced November 19, 2025 by Rep. Buchanan (R-FL) with 82 cosponsors, amends the Social Security Act to mandate Medicare coverage for blood-based Alzheimer's disease and related dementias screening tests beginning January 1, 2028. The bill explicitly defines these tests as FDA-cleared or approved genomic sequencing blood tests or equivalent blood-based tests. This is not an authorization bill with a spending ceiling — it mandates coverage under existing Medicare Part B, meaning CMS must establish a reimbursement rate (likely under the Clinical Laboratory Fee Schedule) once the bill becomes law.
The money trail is structural: Medicare covers approximately 60 million Americans aged 65+. Blood-based dementia screening is currently a cash-pay or limited private-pay market. Mandatory Medicare coverage would make these tests available without patient out-of-pocket costs (after deductible), dramatically expanding the addressable patient population. The bill does not authorize a specific dollar amount; instead, it creates a new mandatory spending category within Medicare Part B. Estimated annual Medicare spending could range from $1B to $3B depending on utilization rates and the final CMS payment rate.
Structural winners are Labcorp ($LH) and Quest Diagnostics ($DGX). Both have existing FDA-cleared blood-based dementia tests on the market. Labcorp's test (amyloid tau panel with NFL) and Quest's AD-Detect both target the exact population and test type described in the bill. Smaller diagnostics players ($QDEL, $RVTY) are also in the blood diagnostics space — QuidelOrtho has a cardiac/neurology assay portfolio, and Revvity operates in the applied genomics space — but neither has a directly comparable FDA-cleared blood-based dementia screening test, making their benefit less direct. Their recent 30-day price declines (-29.7% for QDEL, -5.27% for RVTY) reflect broader sector weakness, not dementia-specific headwinds.
The legislative timeline: the bill is in early stages, referred to Energy & Commerce and Ways & Means in the House. Companion bill S3267 was introduced in the Senate. With 82 cosponsors and bipartisan sponsorship, the bill has strong early support, but must pass both chambers and be signed into law before the January 1, 2028 effective date. The most likely passage window is late 2026 or mid-2027. Investors should monitor committee hearings and markups as key catalysts.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Mandatory Medicare coverage for blood-based dementia screening tests starting January 1, 2028, for tests cleared or approved by the FDA under 510(k), 513(f)(2), or 515.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must add Alzheimer's disease and related dementias early detection screening tests to covered Medicare services under Section 1861(s)(2)(KK) of the Social Security Act.
What happens
Creates a new, permanent Medicare-covered diagnostic category for blood-based dementia tests, driving a large increase in testing volume among the 65+ Medicare population (currently ~60 million beneficiaries). Labcorp's existing FDA-cleared blood-based dementia test (e.g., the amyloid tau neurofilament light chain panel) gains a guaranteed reimbursement pathway.
Stock impact
Labcorp's Diagnostics segment (which generated ~$12B in revenue in FY2025) will see incremental volume growth from its blood-based dementia screening offerings. The test is already commercially available and FDA-cleared; Medicare coverage eliminates the prior authorization barrier and expands addressable patients from out-of-pocket/private-pay to the entire Medicare fee-for-service population. Estimated incremental annual revenue of $150M-$350M assuming $500-$1,000 per test and 300,000-500,000 annual Medicare tests.
What the bill does
Same as $LH — mandatory Medicare coverage for blood-based dementia screening tests starting January 1, 2028, for tests cleared or approved by the FDA.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must add new test code to Medicare Clinical Laboratory Fee Schedule and establish payment rate.
What happens
Quest Diagnostics, which markets its own blood-based dementia test (AD-Detect, measuring amyloid beta 42/40 ratio and apolipoprotein E), gains Medicare reimbursement for a test currently covered only by private payors and cash-pay patients. This opens a large new volume channel in the Medicare population.
Stock impact
Quest's Diagnostic Information Services segment (~$9B annual revenue) will see increased test volume. Quest's AD-Detect test is already available and has an FDA-cleared pathway; Medicare coverage removes the largest barrier to physician ordering. Estimated incremental annual revenue of $100M-$250M assuming $400-$800 per test and 250,000-400,000 Medicare tests per year.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
CHOICE for Veterans Act of 2025
Access to Breast Cancer Diagnosis Act of 2025
Supporting Healthy Moms and Babies Act
Reducing Hereditary Cancer Act
Increasing Access to Lung Cancer Screening Act
Thyroid Disease CARE Act of 2025
Find It Early Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →